Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | August 29, 2012

When PET Fails

We want absolutes; things we can depend on; certainties in an unfortunately uncertain world. It’s the kind of faith we put into positron emission tomography/computed tomography (PET/CT), even when it’s not warranted.

More than a year ago, the German Institute for Quality and Efficiency in Health Care released a study concluding that there was a dearth of support for the use of PET/CT as a reliable aid in diagnosing or monitoring for the return of melanoma. A systematic search found no published studies to indicate the relevance of PET or PET/CT in either primary staging or in the detection of recurrences of malignant melanoma. Nor was any research uncovered indicating the prognostic accuracy of this technique.

In the absence of documented failures or successes, PET/CT continues to be used by some physicians to stage melanoma or monitor patients for its recurrence. Its results are used, consequently, to ease patient worries, sometimes incorrectly.

So it was that a long-time friend of mine, who had been battling melanoma for the past six years, received a PET/CT, embraced its negative findings, then weeks later encountered symptoms that led him to undergo a brain CT, which revealed a large tumor in his parietal and temporal lobes.

In mainstream medical practice, FDG-PET is considered essential for staging and monitoring patients battling cancers such as lymphoma and that of the lung, according to Michael Vannier, M.D., professor of radiology at the University of Chicago. But PET has specific and significant limitations. These are often related to the type of disease, the isotopic agent and the size of the lesion, Vannier explained.

“We sometimes find that PET has been used inappropriately for certain tumor types. Renal cell cancer and prostate cancer are notoriously difficult to image with FDG-PET,” he told me.

Add melanoma to that list.

When PET/CT is used to do what it cannot do effectively, it may be an expression of an old maxim –  that when all you have is a hammer, everything looks like a nail.

In this age of dwindling resources, we need to be a little pickier about what we hammer. The financial costs of doing so indiscriminately are high. Yet they pale when compared to the emotional price paid by patients whose belief in a bright future is unwarranted.

Related Content

St. Cloud Hospital Installs Toshiba Aquilion One Genesis CT for Emergency Department
News | Computed Tomography (CT) | August 23, 2017
Central Minnesota residents now have access to advanced computed tomography (CT) technology that is safe and fast at St...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Patient Complexity, Subspecialization Impact List Prices for Radiologists' Services
News | Business | August 15, 2017
A new study by the Harvey L. Neiman Health Policy Institute finds that patient condition complexity and...
Upcoming radiology conferences, meetings and events.
News | August 14, 2017
ITN maintains a comprehensive listing of radiology specialty meetings on its website at ...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | Computed Tomography (CT) | August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
ACR Establishes Education Committee for Patient- and Family-Centered Care
News | Patient Engagement | August 09, 2017
Members of the new Education Committee of the American College of Radiology (ACR) Commission on Patient- and Family-...
Overlay Init